Pharming Group N.V. Files 6-K with Press Release
Ticker: PHAR · Form: 6-K · Filed: Sep 10, 2025 · CIK: 1828316
| Field | Detail |
|---|---|
| Company | Pharming Group N.V. (PHAR) |
| Form Type | 6-K |
| Filed Date | Sep 10, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, press-release
Related Tickers: PHAR
TL;DR
Pharming Group (PHAR) filed a 6-K on Sept 10, 2025, with a press release attached - check it for news.
AI Summary
Pharming Group N.V. filed a Form 6-K on September 10, 2025, to furnish a press release dated September 10, 2025, as Exhibit 99.1. The filing does not contain specific financial figures or operational details beyond the submission of this press release.
Why It Matters
This filing indicates Pharming Group N.V. is providing updated information to the SEC, likely containing material news for investors.
Risk Assessment
Risk Level: low — This is a routine filing to submit a press release, not indicating any immediate financial distress or significant operational change.
Key Players & Entities
- Pharming Group N.V. (company) — Registrant
- September 10, 2025 (date) — Filing and Press Release Date
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to furnish a press release dated September 10, 2025, as Exhibit 99.1 to the report.
What is the filing date of this Form 6-K?
The filing date is September 10, 2025.
What is the Commission File Number for Pharming Group N.V.?
The Commission File Number is 001-39822.
Where is Pharming Group N.V. headquartered?
Pharming Group N.V. is headquartered at Darwinweg 24, 2333 CR Leiden, The Netherlands.
Does this filing include an annual report?
No, this filing is a Form 6-K, and the company indicates it files annual reports under Form 20-F.
Filing Stats: 851 words · 3 min read · ~3 pages · Grade level 12.8 · Accepted 2025-09-10 06:15:35
Filing Documents
- pharminggrouppromotedtothe.htm (6-K) — 25KB
- logo_greyxoriginalx.jpg (GRAPHIC) — 112KB
- logo_pharmingxoriginal.jpg (GRAPHIC) — 18KB
- 0001828316-25-000041.txt ( ) — 193KB
Forward-looking Statements
Forward-looking Statements This press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management's current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as "aim", "ambition", anticipate'', believe'', could'', estimate'', expect'', goals'', intend'', may'', "milestones", objectives'', outlook'', plan'', probably'', project'', risks'', "schedule", seek'', should'', target'', will'' and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates, Pharming's clinical and commercial prospects, and Pharming's expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming's clinical trials and ramifications for the cost thereof and clinical, scientific, regulatory, commercial, competitive and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming's 2024 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming's actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to